<<Canaccord Genuity reiterates a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR
) price target of $20.00.
Canaccord analyst, George Farmer, said, "OPTR reported 2011 DIFICID gross sales of $24.4M, a total of $12.1M in Q3/11 (includes $5.1M to fully-stock inventory) and $12.2M in Q4/11, with strong Q4 m/m growth of ~11%. End of Q4/11 inventory decreased $1.1M, resulting in Q4/11 ex-wholesaler sales of $13.3M, a 90% increase compared to Q3/11 ex-wholesaler sales of $7M. This is reflected in an 87% increase between Q3 and Q4 of wholesale shipments from 2505 to 4675 treatments. DIFICID shipments to wholesalers in Q4/11 grew at an 11.3% compounded monthly growth rate. We now model for the Euro 50M Astellas milestone payment in Q2/12.">>
There have been a few other analysts who have recently reiterated their targets and buy ratings -- earlier this month. If I recall correctly the lowest estimate was $17.